To assess the treatment of superficial vein thrombosis (SVT) with intermediate dose of tinzaparin in a setting of real world practice.
Methods
Prospective observational study of consecutive patients treated by vascular physicians in the private sector with tinzaparin (131 IU/Kg) once daily. Treatment duration was at the treating physician’s discretion. The outcomes of the study were symptomatic venous thromboembolism, extension of thrombus and bleeding complications.
Results
660 patients were included and followed up for at least 3 months. Median duration of treatment was 30 days (14–120). History of prior deep vein thrombosis (HR 2.77; 95% CI= 1.18–6.49; p = 0.018) and current SVT above the knee (HR1.84; 95% CI = 1.33–3.53; p = 0.0002) were associated with prolonged treatment duration. Primary efficacy outcomes occurred in 20 (3%) patients. The median time to the event was 24 (6–92) days and was not related to treatment duration.
Conclusions
Tinzaparin at intermediate dose is an effective and safe treatment for SVT.
LeonLGiannoukasADoddD, et al.
Clinical significance of superficial vein thrombosis. Eur J Vasc Endovasc Surg2005;
29: 10–17.
2.
DecoususHBertolettiLFrappeP, et al.
Recent findings in the epidemiology, diagnosis and treatment of superficial vein thrombosis. Thromb Res2011;
127: 81–85.
3.
CannegieterSCHorváth-PuhóESchmidtM, et al.
Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study. Blood2015;
125: 229–235.
4.
FrappePBuchmuller-CordierABertolettiL, et al.; STEPH Study Group.
Annual diagnosis rate of superficial vein thrombosis of the lower limbs: the STEPH community-based study. J Thromb Haemost2014;
12: 831–838.
5.
van LangeveldeKLijferingWMRosendaalFR, et al.
Increased risk of venous thrombosis in persons with clinically diagnosed superficial vein thrombosis: results from the MEGA study. Blood2011;
118: 4239–4241.
6.
GalanaudJPGentyCSevestreMA, et al.; OPTIMEV SFMV Investigators.
Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis. The OPTIMEV study. Thromb Haemost2011;
105: 31–39.
7.
DecoususHPrandoniPMismettiP, et al.; CALISTO Study Group.
Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med2010;
363: 1222–1232.
8.
BlondonMRighiniMBounameauxH, et al.
Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis. Chest2012;
141: 321–329.
9.
GoldmanLGinsbergJ.Superficial Phlebitis and phase 3.5 trials. N Engl J Med2010;
363: 1278–1280.
10.
GiannoukasAKarathanosCNikolakopoulosK, et al.; SeVEN Collaborators.
Tinzaparin in intermediate dose for the treatment of superficial vein thrombosis: Results from an observational multicenter study – SeVEN study. Phlebology2018;
33: 636–645.
11.
NikolakopoulosKMKakkosSKPapageorgopoulouCP, et al.
Extended duration treatment of superficial vein thrombosis of the lower limbs with tinzaparin. VSI2018;
34: 1–9.
12.
CosmiBFilippiniMTontiD, et al.; on behalf of the STEFLUX Investigators.
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (superficial ThromboEmbolism and fluxum). J Thromb Haemostasis2012;
10: 1026–1035.
13.
DuffettLKearonCRodgerM, et al.
Treatment of superficial vein thrombosis: a systematic review and meta-analysis. Thromb Haemost2019;
119: 479–489.
14.
DecoususHQuéréIPreslesE, et al.; POST (Prospective Observational Superficial Thrombophlebitis) Study Group.
Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med2010;
152: 218–224.
15.
ChengelisDLBendickPJGloverJL, et al.
Progression of superficial venous thrombosis to deep veins. J Vasc Surg1996;
24: 745–749.
16.
VerlatoFZucchettaPPrandoniP, et al.
An unexpectedly high rate of pulmonary embolism in patients with superficial thrombophlebitis of the thigh. J Vasc Surg1999;
30: 1113–1115.
17.
BellLNBergRLSchmelzerJRLiangH, et al.
Thromboembolic complications following a first isolated episode of superficial vein thrombosis: a cross-sectional retrospective study. J Thromb Thrombolysis2017;
43: 31–37.
18.
SpirkoskaAJezovnikMKPoredosP.Time course and the recanalization rate of superficial vein thrombosis treated with low-molecular-weight heparin. Angiology2015;
66: 381–386.
19.
KarathanosCSpanosKLachanasV, et al.
Patterns in the management of superficial vein thrombosis. Phlebology2017;
32: 207–213.
20.
DuaAHellerJAPatelB, et al.
Variability in the management of superficial venous thrombophlebitis across practitioners based in North America and the global community. Thrombosis2014;
2014: 306018.
21.
Beyer-WestendorfJSchellong SMGerlachH, et al.
Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol2017;
4: 105–113.
22.
Di NisioMWichersIMMiddeldorpS.Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev2018;
2: CD004982.
23.
STENOX study group.
A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med2003;
163: 1657–1663.
24.
KalodikiEStvrtinovaVAllegraC, et al.
Superficial vein thrombosis – a consensus statement. Int Angiol2012;
31: 203–216.
25.
KarathanosCSpanosKSaleptsisV, et al.
Recurrence of superficial vein thrombosis in patients with varicose veins. Phlebology2016;
31: 489–495.
26.
GalanaudJ-PSevestreM-APernodG, et al.
Long-term risk of venous thromboembolism recurrence after isolated superficial vein thrombosis. J Thromb Haemost2017;
15: 1123–1131.
